Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1987 2
1988 14
1989 18
1990 12
1991 14
1992 14
1993 14
1994 24
1995 25
1996 27
1997 20
1998 28
1999 41
2000 45
2001 51
2002 64
2003 51
2004 67
2005 58
2006 76
2007 67
2008 83
2009 96
2010 124
2011 115
2012 121
2013 135
2014 223
2015 282
2016 304
2017 344
2018 317
2019 378
2020 397
2021 381
2022 420
2023 390
2024 381
2025 404
2026 227

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,196 results

Results by year

Filters applied: . Clear all
Page 1
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.
Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée JM, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hankinson SE, Harkness EF, H… See abstract for full author list ➔ Mavaddat N, et al. Am J Hum Genet. 2019 Jan 3;104(1):21-34. doi: 10.1016/j.ajhg.2018.11.002. Epub 2018 Dec 13. Am J Hum Genet. 2019. PMID: 30554720 Free PMC article.
Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. ...This PRS is a powerful and reliable predictor of breast cancer risk that may improve breast …
Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening …
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches.
Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Raheem F, et al. Int J Mol Sci. 2023 Nov 11;24(22):16198. doi: 10.3390/ijms242216198. Int J Mol Sci. 2023. PMID: 38003387 Free PMC article. Review.
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective as the disease progresses. ...In this article, we review the mechanisms of acquired …
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop re …
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Magbanua MJM, et al. Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4. Cancer Cell. 2023. PMID: 37146605 Free PMC article.
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessment. To investigate subtype-specific differences in the clinical significance and biology of ctDNA shedding, we perform serial personalized ct …
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment via non-invasive tumor burden assessmen …
Updates and controversies in breast pathology.
Peng Y, Erickson LA. Peng Y, et al. Hum Pathol. 2025 Aug;162:105864. doi: 10.1016/j.humpath.2025.105864. Epub 2025 Jun 27. Hum Pathol. 2025. PMID: 40582650
In the rapidly evolving molecular era, this special issue on breast pathology aims to provide a timely update on recent advancements and to foster thoughtful discussion on current controversies across the diverse landscape of breast lesions. ...
In the rapidly evolving molecular era, this special issue on breast pathology aims to provide a timely update on recent advancements …
Prophylactic mastectomy.
Zakaria S, Degnim AC. Zakaria S, et al. Surg Clin North Am. 2007 Apr;87(2):317-31, viii. doi: 10.1016/j.suc.2007.01.009. Surg Clin North Am. 2007. PMID: 17498529 Review.
Those most likely to benefit from PM are BRCA gene carriers and those who have a strong family history of breast cancer. Prevetive PM remains controversial, however. There are no randomized controlled trials to substantiate the potential benefit or harms of PM. This …
Those most likely to benefit from PM are BRCA gene carriers and those who have a strong family history of breast cancer. Preve …
Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Guidugli L, Shimelis H, Masica DL, Pankratz VS, Lipton GB, Singh N, Hu C, Monteiro ANA, Lindor NM, Goldgar DE, Karchin R, Iversen ES, Couch FJ. Guidugli L, et al. Am J Hum Genet. 2018 Feb 1;102(2):233-248. doi: 10.1016/j.ajhg.2017.12.013. Epub 2018 Jan 25. Am J Hum Genet. 2018. PMID: 29394989 Free PMC article.
VUS pose a significant clinical challenge because the contribution of these variants to cancer risk has not been determined. We conducted a comprehensive assessment of VUS in the BRCA2 C-terminal DNA binding domain (DBD) by using a validated functional assay of BRCA2 homol …
VUS pose a significant clinical challenge because the contribution of these variants to cancer risk has not been determined. We condu …
Breast cancer-related lymphedema.
Morrell RM, Halyard MY, Schild SE, Ali MS, Gunderson LL, Pockaj BA. Morrell RM, et al. Mayo Clin Proc. 2005 Nov;80(11):1480-4. doi: 10.4065/80.11.1480. Mayo Clin Proc. 2005. PMID: 16295027 Review.
Every year in the United States, breast cancer is diagnosed in more than 200,000 women. Because of the prevalence of breast cancer, treatment-related sequelae are of Importance to many survivors of the disease. ...This review presents an overview of th …
Every year in the United States, breast cancer is diagnosed in more than 200,000 women. Because of the prevalence of breast …
Evidence-Based Guidance for Breast Cancer Survivorship.
Cathcart-Rake EJ, Ruddy KJ. Cathcart-Rake EJ, et al. Hematol Oncol Clin North Am. 2023 Feb;37(1):225-243. doi: 10.1016/j.hoc.2022.08.019. Hematol Oncol Clin North Am. 2023. PMID: 36435612 Review.
Breast cancer survivorship care includes management of lingering physical symptoms, supports to address the emotional toll exacted by a cancer diagnosis and cancer therapies, monitoring and optimization of cardiac and bone health, general wellness prom …
Breast cancer survivorship care includes management of lingering physical symptoms, supports to address the emotional toll exa …
Radiation-induced breast sarcoma.
Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Blanchard DK, et al. Am J Surg. 2002 Oct;184(4):356-8. doi: 10.1016/s0002-9610(02)00943-1. Am J Surg. 2002. PMID: 12383902
BACKGROUND: The purpose of this study was to examine the presentation, treatment, and prognosis of patients with radiation-induced sarcomas after adjuvant radiotherapy for breast cancer. METHODS: This was a retrospective review from 1975 to 2001 of patients who pres …
BACKGROUND: The purpose of this study was to examine the presentation, treatment, and prognosis of patients with radiation-induced sarcomas …
Breast cancer-related paraneoplastic neurologic disease.
Murphy BL, Zalewski NL, Degnim AC, McKeon A, Flanagan EP, Pittock SJ, Habermann EB. Murphy BL, et al. Breast Cancer Res Treat. 2018 Feb;167(3):771-778. doi: 10.1007/s10549-017-4566-0. Epub 2017 Nov 7. Breast Cancer Res Treat. 2018. PMID: 29116466
Given the rarity, a paucity of data describing breast cancer-related PND (BC-PND) exists; we sought to further examine this specific patient population. ...Retrospective review with a descriptive analysis determined factors associated with PND and BC, which were com …
Given the rarity, a paucity of data describing breast cancer-related PND (BC-PND) exists; we sought to further examine this sp …
5,196 results